Glioblastom multiform. Brain, unspecified
Conditions
Interventions
Intervention 1: Intervention Group will receive radiotherapy plus Temozolomide and Metformin 1g daily. The patients should take Metformin durng radiotherapy and after that till primay endpoint. Interv
Treatment - Drugs
Intervention Group will receive radiotherapy plus Temozolomide and Metformin 1g daily. The patients should take Metformin durng radiotherapy and after that till primay endpoint.
Control Group will receive radiotherapy and Temozolomide as routine adjuvant treatment.
Sponsors
Kerman Neuroscience Research Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: inclusion: GBM diagnosis confirmed by pathology; age>18; KPS>60; normal kidney function exclusion:; no underlining disease which interfere the course of treatment a life threatening diseases other than GBM; DM; infectious disease ; lactation or pregnancy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival. Timepoint: monthly. Method of measurement: alive or dead. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival. Timepoint: based on clinical deterioration. Method of measurement: deterioration of KPS of appearance of new lesion. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Eskandary
Kerman Neuroscience Research Center
Outcome results
None listed